

Influenza Work Group—Introduction

Dr. Jamie Loehr (Work Group Chair)

Advisory Committee on Immunization Practices
October 23, 2024

Influenza Work Group

ACIP Members

- Jamie Loehr (Chair)
- Robert Schechter
- Albert Shaw
- Keipp Talbot

Ex Officio

- Timothy Brennan (FDA)
- Uzo Chukwuma (IHS)
- Michael Ison (NIH)
- Cynthia Nolletti (FDA)
- Jo Resnick (FDA)
- Chris Roberts (NIH)

Liaison Representatives and Consultants

- Robert Atmar
- Kevin Ault
- Ed Belongia
- Hank Bernstein
- Kris Bryant
- Doug Campos-Outcalt
- Sarah Coles
- Frances Ferguson
- Sandra Fryhofer
- Robert Hopkins
- Wendy Keitel
- Camille Kotton
- Marie-Michèle Léger
- Susan Lett
- Krissy Moehling
- Zackary Moore
- Rebecca Morgan
- Flor Munoz
- Caitlin Newhouse
- Jesse Papenburg
- William Schaffner
- Ken Schmader
- Tamara Sheffield
- Angela Sinilaite
- Peter Szilagyi
- Matthew Zahn

CDC Lead

- Lisa Grohskopf

CDC Participants

- Lenee Blanton
- Karen Broder
- Alicia Budd
- Jessie Chung
- Jennifer DeCuir
- Sascha Ellington
- Tarayn Fairlie
- Jill Ferdinands
- Brendan Flannery
- Andrew Kroger
- Samantha Olson
- David Shay
- Tom Shimabukuro
- Naomi Tepper

Brief Note

Update concerning FluMist (Live Attenuated Influenza Vaccine, Trivalent; LAIV3)

- On September 20, 2024, FDA approved FluMist for self or caregiver administration.
- For the current 2024-25 influenza season, FluMist is available for administration by a healthcare provider only.
- It is anticipated that FluMist will be available for self or caregiver administration for the 2025-26 influenza season.

2023-24 Season Influenza Vaccine Effectiveness (VE)

Issue:

- Influenza vaccine effectiveness (VE) varies and is assessed annually through several CDC platforms focusing on laboratory-confirmed influenza outpatient visits and hospitalizations in adult and pediatric populations.
- Preliminary 2023-24 season VE estimates were presented at the February 2024 ACIP meeting.

Updates:

- ***2023–24 End of Season Influenza Vaccine Effectiveness – United States***
 - *Dr. Sascha Ellington, Influenza Division, CDC/NCIRD*
- This topic is presented for information and discussion.

Avian Influenza A(H5N1) Update

Issue:

- Influenza A(H5N1) has been detected in U.S. dairy herds in 14 U.S. states
- 27 human cases have been reported during 2024.

Updates:

- ***Highly Pathogenic Avian Influenza A(H5N1) Update***
 - *Dr. Tom Shimabukuro; Deputy Director, Influenza Division, CDC/NCIRD*
- This topic is presented for information and discussion.

<https://www.cdc.gov/bird-flu/situation-summary/index.html>

Vaccines for Children (VFC) Vote

Issue:

- High-dose inactivated (HD-IIV3) and adjuvanted inactivated (aIIV3) influenza vaccines are approved in the United States for ages ≥ 65 years.
- An evidence review of HD-IIV3 and aIIV3 for solid organ transplant (SOT) recipients ages ≥ 6 months was presented at the June 2024 ACIP meeting.
- ACIP voted to recommend that HD-IIV3 and aIIV3 are acceptable options for SOT recipients aged 18 through 64 years who are receiving immunosuppressive medication regimens, without a preference over other age-appropriate inactivated or recombinant vaccines.

Vote:

- A VFC resolution is proposed to add options for vaccination of 18-year-olds who are solid organ transplant recipients.
 - *Dr. Jeanne Santoli, CDC/NCIRD*

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

